- Home
- RUM vs PTGX Comparison
RUM vs PTGX Comparison
Compare RUM & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RUM
- PTGX
- Stock Information
- Founded
- RUM 2013
- PTGX 2006
- Country
- RUM United States
- PTGX United States
- Employees
- RUM N/A
- PTGX N/A
- Industry
- RUM Computer Software: Prepackaged Software
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- RUM Technology
- PTGX Health Care
- Exchange
- RUM Nasdaq
- PTGX Nasdaq
- Market Cap
- RUM 2.4B
- PTGX 3.7B
- IPO Year
- RUM N/A
- PTGX 2016
- Fundamental
- Price
- RUM $7.75
- PTGX $62.14
- Analyst Decision
- RUM Buy
- PTGX Strong Buy
- Analyst Count
- RUM 2
- PTGX 9
- Target Price
- RUM $15.00
- PTGX $70.44
- AVG Volume (30 Days)
- RUM 2.0M
- PTGX 948.7K
- Earning Date
- RUM 11-11-2025
- PTGX 11-06-2025
- Dividend Yield
- RUM N/A
- PTGX N/A
- EPS Growth
- RUM N/A
- PTGX N/A
- EPS
- RUM N/A
- PTGX 0.80
- Revenue
- RUM $104,076,612.00
- PTGX $209,180,000.00
- Revenue This Year
- RUM $14.63
- PTGX N/A
- Revenue Next Year
- RUM $34.05
- PTGX $248.17
- P/E Ratio
- RUM N/A
- PTGX $76.66
- Revenue Growth
- RUM 32.45
- PTGX N/A
- 52 Week Low
- RUM $5.03
- PTGX $33.31
- 52 Week High
- RUM $17.40
- PTGX $62.17
- Technical
- Relative Strength Index (RSI)
- RUM 52.19
- PTGX 62.68
- Support Level
- RUM $7.36
- PTGX $57.90
- Resistance Level
- RUM $7.75
- PTGX $60.40
- Average True Range (ATR)
- RUM 0.29
- PTGX 2.48
- MACD
- RUM 0.09
- PTGX 0.09
- Stochastic Oscillator
- RUM 84.79
- PTGX 99.22
About RUM Rumble Inc.
Rumble Inc is a free-to-use video-sharing platform where users can watch, share, like, comment, and upload their own videos. Users can subscribe to channels to stay in touch with recent creator content and access video-on-demand uploaded, and live content streamed, by creators. Geographically, it generates a majority of its revenue from the United States.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.